Abstract: Erectile dysfunction (ED) is a highly prevalent disease associated with aging as well as with several risk factors including hypertension, heart disease, obesity, dyslipidemia, diabetes, hypogonadism, drugs-related, and pelvic surgery. Many of these factors are components of the metabolic syndrome, a multiplex risk factor for cardiovascular disease (CVD). ED shares common risk factors with CVD. Endothelial dysfunction seems to be the early underlying pathophysiology across both conditions. The effi cacy, tolerability and cardiovascular safety of sildenafi l has been evaluated in numerous large, randomized, double-blind, placebo-controlled clinical studies in the broad population of men with ED including men with several co-morbid conditions. Sildenafi l is effective in several specifi c patient populations including the diffi cult-totreat subpopulations such as diabetes mellitus and after radical prostatectomy. It is associated with rapid onset of action -within 14 minutes for some men -and an extended duration of action for up to 12 hours. Sildenafi l improves quality of life and satisfaction for treated men and is well tolerated with a favorable safety profi le. New data suggest that sildenafi l has benefi cial effects in several chronic conditions. It has been approved for the treatment of idiopathic pulmonary hypertension. Numerous articles have suggested that it improves endothelial function and a possible role on premature ejaculation or treatment of lower urinary tract symptoms has been suggested.
Introduction
Erectile dysfunction (ED) is a highly prevalent disease, as well as a major sexual concern for men (Braun et al 2000; Martin-Morales et al 2001; Papaharitou et al 2006) . The prevalence of ED is increasing with age. The Massachusetts Male Aging Study (MMAS) demonstrated a 40% prevalence of ED in men aged 40 years that increased to almost 70% in men aged 70 years (Feldman et al 1994) . As the proportion of older people in the population increases, it has been estimated that the worldwide prevalence of ED will double from 152 million men in 1995 to 322 million men in 2025 (Aytac et al 1999) . ED is also associated with other conditions such as age, smoking, hypertension, heart disease, diabetes, and as a consequence of radical prostatectomy. Cardiovascular disease (CVD) and ED share common risk factors and refl ect endothelial dysfunction (Kostis et al 2005) . There is an increasing body of evidence that ED is the fi rst sign of CVD in men with free medical history and may present well before CVD with a mean time-interval of even 3 years (Montorsi et al 2003) .
The availability of phosphodiesterase type 5 inhibitors (PDE5i) has resulted in increasing numbers of patients seeking medical help for erectile function problems, but has also altered dramatically the medical management of ED (Hatzichristou and Pescatori 2001; Lewis et al 2001; Steers et al 2001) . More physicians are treating ED, especially in the primary care setting, including minimal patient work-up and prescription of PDE5i due to their proven effi cacy and safety profi le.
The management of ED by non-specialists includes minimal patient work-up and prescription of exclusively fi rst-line treatment options in most cases, mainly due to the lack of time and background knowledge (Hatzichristou 2002) . Sildenafi l was the fi rst available PDE5i that revolutionized ED treatment (Goldstein et al 1998) . More than 30 million of men are treated worldwide with sildenafi l accompanied by vast experience and research with more than 2600 papers published in Medline as of July 2006. Furthermore, new data suggest that sildenafi l has benefi cial effects in several chronic conditions. It has been recently approved for the treatment of idiopathic pulmonary hypertension (Galie et al 2005) , and numerous articles have suggested that PDE5i may improve endothelial function (Katz et al 2000; Desouza et al 2002; Halcox et al 2002; Vlachopoulos et al 2003; Vlachopoulos et al 2004; Gori et al 2005; Hirata et al 2005) . PDE5i have been also suggested to be benefi cial for patients with premature ejaculation (Abdel-Hamid 2004) . However, clinical studies have shown controversial results so far (Salonia et al 2002; Chen et al 2003; Atan et al 2006) and it remains uncertain, whether PDE5i act on the physiologic process of ejaculation, or indirectly, improving erectile function and therefore, reducing performance anxiety in men with ED.
The aim of this review is to provide an overview of the clinical evidence associated with sildenafi l in the treatment of ED as well as to present data from ongoing basic and clinical research in other chronic diseases.
Pharmacological profi le: time to onset and duration of action
Sildenafil is a highly selective inhibitor of PDE type 5 (Boolell et al 1996; Gbekor et al 2002) . It enhances NO-mediated relaxation of human corpus cavernosum in vitro (Ballard et al 1998; Stief et al 1998; Gemalmaz et al 2001) . Sildenafil, by inhibiting phosphodiesterase, increases the intracellular concentrations of cyclic guanosine 3',5' monophosphate (cGMP), causing an amplification of the endogenous NO-cGMP signaling pathway.
The time to maximum plasma concentration is about 1 h while the plasma half-life is about 4-5 h. It is administered orally on demand in 25 mg, 50 mg, and 100 mg doses. The recommended starting dose is 50 mg and adapted according to effi cacy and tolerability. Patients are instructed to take sildenafi l approximately 1 h before sexual intercourse with a maximum dosing frequency of once daily. Sexual stimulation is a prerequisite for sildenafi l as well as for the other PDE5i.
The window of opportunity to engage in sexual intercourse is maintained from 30 min to 4-5 h from administration. However, the onset of action can be 14 min for about 35% of patients (Figure 1 ) and effi cacy may be maintained for up to 12 h (Moncada et al 2004) . A heavy fatty meal results in reduced and prolonged absorption. Alcohol does not have an impact on absorption in regular doses. Contraindications for the use of sildenafi l and need for dose adjustments are summarized in Table 1 (Langtry and Markham 1999) .
Effi cacy in broad populations of men with ED
The fi rst data on effi cacy of sildenafi l were published by Goldstein and colleagues (1998) successful in 69% of all attempts for the men receiving sildenafi l, as compared with 22% for those receiving placebo (p<0.001). The mean numbers of successful attempts per month were 5.9 for men receiving sildenafi l and 1.5 for those receiving placebo (p<0.001). Effi cacy parameters for sildenafi l in 11 double-blind, placebo controlled, pre-marketing studies included the International Index of Erectile Function (IIEF) erectile function domain score and especially the questions 3 and 4 (ability to attain and ability to maintain an erection suffi cient for intercourse respectively) as well as the general effi cacy question (GEQ). In 6 of the 11 trials, patients maintained an event log of sexual activity. Patients were stratifi ed in subgroups in terms of age, race, body mass index (BMI), duration of ED, ED etiology, smoking status, and concomitant conditions/medications ( Figure 2 ). All subgroups were well balanced between placebo and sildenafi l. After 12 weeks of treatment, 46.5% to 87% of patients in the subgroups receiving sildenafi l indicated that treatment had improved their erections compared with 11.3% to 41.3% of patients in subgroups receiving placebo. In the 6 trials in which sexual event log data were collected, signifi cantly greater percentages of successful attempts at intercourse were reported by patient subgroups receiving sildenafi l (52.6% to 80.1%) compared with patient subgroups receiving placebo (14.0% to 34.5%). All differences were statistically signifi cant (Carson et al 2002) .
Long-term effectiveness of sildenafi l was assessed in 3 open-label, fl exible-dose (25 mg to 100 mg) studies. After 12 months of treatment (3 years in one study) or at the time of discontinuation, patients were asked if they were satisfi ed with the effect of the medication on erections, and if the treatment improved their ability to engage in sexual activity. Satisfaction and improvement in ability to engage in sexual activity reported in 96% and 99% of patients respectively. Of the 11% of patients who discontinued treatment, 2% discontinued for treatment-related reasons (1.6% for insuffi cient response, 0.4% for adverse events). These satisfaction rates maintained for 3 years in one study. Over the 3-year period, 32% of patients discontinued treatment. Only 6.7% of discontinuations were treatment related (5.7% for insuffi cient response, 1% for treatment-related adverse events). The remaining 25.3% of patients discontinued for reasons not related to treatment (eg, non-treatment-related adverse events, lost to follow-up evaluation, withdrawn consent, and protocol violations). Most patients were receiving 100 mg sildenafi l doses (88% at 3 years) (Carson et al 2002) . Similar effi cacy rates for sildenafi l were reported in clinical practice setting. An improvement in ability to achieve erections was reported by 68% and 71% of patients with ED (Marks et al 1999; McMahon et al 2000) . Success with sildenafi l, defi ned as 75% successful intercourse, was reported by 82% of patients with 77% being successful at every attempt . 
Effi cacy in subpopulations of men with ED
The effi cacy of sildenafi l in almost every subgroup of patients with ED is more than established. Response rates in elderly men (≥65 years) are comparable with general population regardless of age (Wagner et al 2001) . No differences in response rates were demonstrated in ethnic groups (Young et al 2002) . In type 1 diabetic patients, 66.6% reported improved erections (GAQ) and 63% reported successful intercourse attempts compared with 28.6% and 33% by those taking placebo, respectively (Stuckey et al 2003) . In another multicenter, randomized, double-blind, placebo-controlled, fl exible dose-escalation study in diabetic patients, 56% of patients reported improved erections and 61% reported at least 1 successful intercourse attempt compared with 10% and 22% in the placebo group, respectively (Rendell et al 1999) . Diabetic patients are one of the most diffi cult to treat subgroups (Behrend et al 2005) . In patients after bilateral nerve-sparing radical prostatectomy, 76% responded to sildenafi l (defi ned as successful vaginal intercourse) (Raina et al 2004) . A favorable response to sildenafi l in patients with ischemic heart disease (GEQ and IIEF Q3 and Q4) who were receiving b-blockers and/or angiotensin-converting enzyme inhibitors and/or calcium channel blockers has been observed (Olsson and Persson 2001) . Similar results presented in patients with hypertension (taking different or multiple antihypertensive drugs). High effi cacy rates presented in patients on chronic dialysis for renal failure (lower doses and longer intervals between treatments are usually required) (Chen et al 2001; Mahon et al 2005) , after renal transplantation (Prieto Castro et al 2001; Sharma et al 2006) , in spinal cord injuries (Derry et al 2002; Deforge et al 2006) and patients with depression (treated with selective serotonin reuptake inhibitors [SSRIs] or not) (Seidman et al 2001; Nurnberg et al 2002) or patients treated with antipsychotic agents (Gopalakrishnan et al 2006) .
Treatment satisfaction and quality of life
Both patients and partners report higher levels of satisfaction (assessed with the Erectile Dysfunction Inventory of Treatment Satisfaction [EDITS] questionnaire) after sildenafi l treatment relative to placebo (Lewis et al 2001) . Patients receiving sildenafi l had signifi cantly higher scores (73.6 ± 3.2) than did those receiving placebo (48.4 ± 3.2, p<0.001). The scores on the partner version of the EDITS were also signifi cantly higher among the partners of men who received sildenafi l (63.9 ± 8.1) than among the partners of those who received placebo (33.3 ± 7.5, p<0.001). A high level of treatment satisfaction (65%) reported in another clinical practice study (assessed by 5-item scale) (Jarow et al 1999) . Treatment satisfaction was correlated with ED severity (41% in severe, 78% in moderate, and 100% in mild ED) and etiology (56% in neurologic causes, 58% in diabetes, 35% in radical prostatectomy, 89% in psychogenic causes, and 86% in vasculogenic causes). However, no particular characteristic predicted absolute failure with sildenafi l. Sildenafi l also improved all aspects of health-related quality of life (assessed by SF-36 or Q13 and Q14 of the IIEF) in general ED population or subgroups such as spinal cord injuries (Hultling et al 2000; Giuliano et al 2001; Fujisawa et al 2002) . Signifi cant improvements in self-esteem, confidence, sexual relationship satisfaction, and overall relationship satisfaction after treatment of ED with sildenafi l were reported by Althof and colleagues (2006) using the self-esteem and relationship questionnaire (SEAR) in a cross-cultural double-blind, placebo controlled, fl exible dose study Cappelleri et al 2006) . Treatment satisfaction is also maintained through time (Figure 3 ) (Carson et al 2002) .
Data on partner satisfaction support the patients' satisfaction. For the partners of sildenafi l-treated patients, 74% (younger than 65 years) and 67% (65 years or older) were satisfi ed with the treatment compared with the partners of placebo-treated patients (35% and 22% respectively) (Montorsi and Althof 2004) . Satisfaction defi ned as EDITS score of greater than 50. The quality of partnership as perceived by both the men and their female partners is signifi cantly better in ED patients treated with sildenafi l than in untreated controls (Muller et al 2001) . More than 90% of partners reported satisfaction with treatment in an open prospective study of men with ED receiving sildenafi l for 10 weeks .
Sildenafi l in the treatment of erectile dysfunction Safety Adverse events and discontinuation rates Sildenafi l has been on the market for more than 8 years. Morales and colleagues (1998) provided summarized safety until 1998 and Padma-Nathan and colleagues (2002) provided long-term safety data (>4 years). The most commonly reported treatment-related adverse events are headache, facial fl ushing, dyspepsia, dizziness, nasal congestion, abnormal vision, and palpitation (Table 2) . Other adverse events uncommonly or rarely reported include back pain, infl uenza-like syndrome, rash, vomiting, diarrhea, cardiac arrhythmia, and hypersensitivity reactions. Adverse events are dose related, mild in nature, self-limited by continuous use. The drop-out rate due to adverse events is similar to placebo (2% for sildenafi l vs 2.3% for placebo). Post-marketing case series reported higher incidence of adverse events, especially for headache (9%-39%), fl ushing (7%-33%) and abnormal vision (5%-11%) (Zippe et al 1998; Jarow et Ischemic heart disease and hypertension are associated with higher incidence of adverse events than diabetes (3.6%, 2.3%, and 1.9%, respectively) (Padma-Nathan et al 2002). Visual disturbances (blurred vision, fl ashing lights, blue haze, and change in color perception) occur due to weak inhibition of PDE6 in the retina. They are coincident with peak plasma concentrations of sildenafi l and are transient and fully reversible. None persisted 6 hours after taking sildenafi l and rarely consist a reason to discontinue treatment.
Cardiovascular safety
Clinical trials and post marketing data of sildenafi l demonstrated no increase in myocardial infarction rates in patients Several new studies have proven not only the cardiovascular safety of sildenafi l, but have also suggested that sildenafi l may have a cardioprotective role. PDE5A inhibition by sildenafi l blunts systolic responses to beta-adrenergic stimulation suggesting a possible role in modifying stimulated cardiac function (Borlaug et al 2005) . Chronic inhibition of cGMP phosphodiesterase 5A by sildenafi l prevents and reverses cardiac hypertrophy (Takimoto et al 2005) . Finally, sildenafi l is the only PDE5i that improved arterial oxygenation in patients with pulmonary hypertension (Ghofrani et al 2004) and it has been recently approved in doses of 20 mg and 40 mg, taking every 8 h life-long by patients with pulmonary hypertension (Galie et al 2005) .
Princeton guidelines on use of PDE5i
The Princeton Consensus Recommendations were developed to provide instructions to physicians who treat men with CVD and ED and answer the most common question: is it safe to take PDE5i and engage in sexual activity? (Kostis et al 2005) . Physicians should consider the cardiovascular status of their patients seeking treatment for ED since there is a degree of risk associated with sexual activity. Three risk categories of CVD were described. Patients in the low risk category (controlled hypertension, stable angina, successful coronary revascularization, history of uncomplicated myocardial infarction, mild valvular disease, and no symptoms with <3 cardiovascular risk factors) can be safely encouraged to initiate or resume sexual activity or receive treatment for their sexual dysfunction. Patients in the intermediate-risk category include those with moderate angina, recent myocardial infarction (<6 weeks), left ventricular dysfunction and/or class II congestive heart failure, non-sustained low-risk arrhythmias and ≥3 risk factors for coronary artery disease. These patients should receive further cardiologic evaluation to determine if they can be restratifi ed into the low-or highrisk cardiovascular categories. Finally, patients in the highrisk category should be stabilized for their cardiac condition before resuming sexual activity or receiving treatment for their sexual dysfunction. It is important to emphasize that the use of any form of nitrate with all PDE5i is contraindicated because of the increased likelihood of hypotension.
Sildenafi l and alpha adrenergic antagonists
Alpha adrenergic antagonists are commonly used drugs in patients with BPH-related LUTS. Although the adverse event profi le of sildenafi l is not worsened by a background of antihypertensive medicines, even when the patient is on multiple antihypertensive agents, it appears to have some interaction with alpha blockers, which may result in clinically signifi cant orthostatic hypotension under some conditions (Kostis et al 2005) . This is most likely to occur in patients treated with doxazosin (a long-acting alpha blocker). Today, alpha blockers are no longer considered a contraindication for sildenafi l, but precautions in the use of these drugs are listed. Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of sildenafi l. Therefore, patients should be stable on alpha-blocker therapy prior to initiating sildenafi l. Treatment with sildenafi l must be initiated at the lowest recommended dose, while it should be taken 3-4 h apart from antihypertensive administration.
Sildenafi l and non-arteritic anterior ischemic optic neuropathy (NAION)
Non-arteritic anterior ischemic optic neuropathy (NAION) is characterized by acute ischemia of the anterior portion of the optic nerve in the absence of provable arteritis, which may result in visual fi eld defect or vision loss. No effective treatment is available and prevention is limited to the treatment of risk factors mainly aiming at decreasing the risk of a similar event in the fellow eye. Numerous risk factors have been reported for NAION, mainly cardiovascular risk factors, including hypertension, diabetes, and hypercholesterolemia. Lastly, the potential relationship between non-arteritic anterior ischemic optic neuropathy (NAION) and PDE5i use has raised important questions and a strong reaction not only among regulatory agencies, but also within the scientifi c community and mass media as well.
There are 16 NAION case reports published in association with sildenafi l. A few of the cases associated with sildenafi l use experienced temporary partial visual loss that became a fi xed visual loss upon rechallenge (Hatzichristou 2005) . As sildenafi l has been used by more than 30 million men worldwide and the incidence of NAION has been reported Sildenafi l in the treatment of erectile dysfunction as 2.3 per 100 000 persons, we would expect far more than the reported 16 cases associated with the use of sildenafi l. According to the European Medicines Agency (EMEA) labeling however, patients taking or considering taking PDE5i should inform their healthcare professionals if they have ever had severe loss of vision, which might refl ect a prior episode of NAION, as such patients are at an increased risk of developing NAION again and they should be referred to the ophthalmologist (Wespes et al 2006) .
Management strategy for treatment failures
Defi nition of treatment failure to sildenafi l Although the term 'treatment failure' to oral drugs is widely used, there is no precise defi nition of what exactly means. Treatment failure may be due to medication, clinician and patient issues (Table 3) . Based on these issues a defi nition of a non-responder to oral pharmacotherapy is proposed: "an inadequate erectile response after at least 4 attempts of the highest tolerated drug dose in accordance with manufacturer's guidelines with respect to timing relative to meals, alcohol ingestion, use of concomitant medications, and adequate sexual stimulation/arousal" (Carson et al 2004) .
Besides these reasons for inappropriate intake of sildenafi l, one of the most common causes of discontinuation of a drug that is considered as treatment failure is the lack of follow-up of the patients. Erectile dysfunction is a chronic disease. Follow-up visits are essential to improve physicianpatient communication, solve treatment problems that may have occurred, identify any change in potency status or new medical conditions and offer continuing education to patients and their partners. These essential aspects in managing ED patients can be easily remembered by the acronym, FAST (Follow-up of patients, Adjustment of time of administration, Sexual stimulation, and Titration to the maximum tolerated dose) (Hatzichristou 2002) .
Identifying truly treatment failures
In order to identify truly treatment failures, the physician need to address all the medication, clinician and patient/partner issues that were previously presented. The probability of a misdiagnosis due to incomplete basic diagnostic evaluation from a non-expert physician must also be investigated . These are patients with hypogonadism or hyperprolactinemia who need specifi c hormonal manipulation in order to cure erectile dysfunction (Greenstein et al 2005) , patients with Peyronie's disease who need treatment for penile curvature or pain during intercourse, and patients who do not have erectile dysfunction but they experience ejaculatory dysfunction or sensory disturbances.
After proper counseling and instructions were given, the patient is encouraged for a re-trial of the oral drug for at least 4 attempts for intercourse with the new instructions on administration, as a recent study revealed inappropriate intake of sildenafi l in 56% of treatment failures . After adequate instructions on the proper use of sildenafi l, one third of the initially non-responders to sildenafi l converted to responders. The most easily reversible factor for treatment failure was the administration of sildenafi l just before initiation of sexual activity followed by absence of sexual desire on sildenafi l uptake and use of the drug with a full stomach. In this study, 12% of sildenafi l failures were not aware that sexual stimulation was mandatory to achieve an erection, but 50% of them converted to responders when they were explained that sildenafi l does not possess aphrodisiac properties. Additionally, 63.6% of the patients who initially used the drug just before the initiation of sexual intercourse and 34.4% of those who took sildenafi l with a full stomach responded to sildenafi l with appropriate timing of administration.
Similar results were presented by other studies. Incorrect administration accounted for 81% of sildenafil failures referred by primary care physicians (Atiemo et al 2003) .
Reasons included administration after heavy meals, lack of sexual stimulation, short timing to intercourse, and too few attempts for intercourse. The authors were able to salvage 41.5% of nonresponders after reeducation as measured by the General Assessment Question (GAG) and Sexual Health Inventory for Men (SHIM) scores. Gruenwald and colleagues (2006) showed that counseling and dose adjustment were directly infl uential in achieving an excellent response to a second trial of sildenafi l in patients with ED who had previously failed treatment with the drug, and obviated their needing to seek more invasive measures. In this study, 38% of the included patients did not receive any explanations or counseling whatsoever from the prescribing physician. After proper instruction, erectile function domain scores increased signifi cantly and overall 23.6% of the patients had a normal IIEF EF domain score (≥26) at the end of the study. A patient is considered as truly non-responder, if retrial of oral therapy after proper counseling and instruction administration fails.
Treatment of truly non-responders
Today, it is widely accepted that treatment approach follows a step-wise model. A patient failing oral pharmacotherapy has to go on second line therapies that include intracavernosal injections and combination treatments. If he further fails second line therapies, the only option is a third line therapy that is implantation of a penile prosthesis.
Preliminary data show that higher doses of sildenafi l (up to 200 mg) may salvage some patients who where sildenafi l nonresponders. McMahon (2002) concluded that sildenafi l at doses of up to 200 mg is an effective salvage therapy for 24.1% of previous sildenafi l non-responders but is limited by a signifi cantly higher incidence of adverse effects and a 31% treatment discontinuation rate. McMahon and colleagues (1999) also used sildenafi l as salvage therapy in intracavernosal injection non-responders (alprostadil or tri-mix). They were able to salvage 31% of patients with combination of sildenafi l with intracavernosal injection of tri-mix. However, combination therapy was associated with a 33% incidence of adverse effects, including a 20% incidence of dizziness side effects (McMahon et al 1999) . Finally, preliminary data suggest a possible role for combination treatment with cabergoline (Safarinejad 2006) or statins (Herrmann et al 2006; Osborne 2006) in non-responders to sildenafi l alone.
Intracavernosal injections remain an excellent treatment option with proven effi cacy and safety over time. Baniel and colleagues (2001) treated sildenafi l non-responders after radical prostatectomy with intracavernosal injections of vasoactive drugs with 85% success rate. Shabsigh and colleagues (2000) were able to salvage sildenafi l non responders with intracavernosal injections of alprostadil. More than 85% improvement in Q3 and Q4 of the IIEF was recorded (Shabsigh et al 2000) . The tri-mix combination (papaverine, phentolamine, alprostadil) is certainly the more effi cacious drug treatment for erectile dysfunction and can be used in severe cases of erectile dysfunction when intravernous alprostadil fails or it is not preferable due to side effects.
The patient should be given every opportunity to choose among options, and to determine which fi ts best to his special needs and expectations. The clinician should also provide a supportive environment for shared decision-making. This management strategy must be supplemented by a careful follow-up in order to identify changes in patients' expectations, possible side effects that may need treatment optimization.
Use of sildenafi l in aging men
The normal aging process and age related risk factor accumulation contribute to the increased prevalence of erectile dysfunction in the elderly. Systemic changes and alterations in the structure and function of the penis in elderly men include hormonal changes (mainly testosterone decrease and increase in sex hormone binding globulin that resulting decreased bioavailability of testosterone) (Margolese 2000) , decrease in elastic fi bers and increase in collagen fi bers in the tunica albuginea (Akkus et al 1997) and molecular changes (decrease in nitric oxide synthase) (Andrew and Mayer 1999) .
Older men (aged ≥65 years) have higher plasma concentrations of sildenafi l compared with younger men (18-45 years), with mean maximum concentration (C max ) 70% greater in older men and mean area under the curve (AUC) 84% higher compared with the younger age group. Due to age-differences in plasma protein binding, the corresponding increase in free sildenafi l plasma concentration was approximately 40%. However, no differences in the safety of any dose of sildenafi l were observed in older patients compared with younger men. Therefore, dosage adjustments are not required in elderly patients (Seftel 2003) . Sildenafi l signifi cantly improves erectile function in elderly patients with erectile dysfunction of broad etiology although effi cacy rates may be lower compared with younger men due to the normal aging process and age related risk factor accumulation mentioned before (Rendell et al 1999; Wagner et al 2001; Carson et al 2002) .
Sildenafi l in the treatment of erectile dysfunction
The need for a patient-centered care model in sexual medicine Erectile dysfunction is a self-reported condition by the patients and the results of different treatment modalities are also self-evaluated (Hatzimouratidis and Hatzichristou 2005) . Recent data on ED treatment outcome have shown that many patients discontinue treatment, despite the availability of effi cacious pharmacotherapies, because doctors fail to inform patients properly and to ensure continuity in care, as well as to be routinely involved in asking patients about their needs and expectations (Mulhall et al 1999; Hatzichristou et al 2005) . Althof (2002) described several causes that may contribute, including the length of time the couple were asexual before seeking treatment, the man's approach to resuming a sexual life with his partner, the female partner's physical and emotional readiness to resume lovemaking, the meaning for each partner of using a medical intervention to enable intercourse and the quality of the nonsexual aspects of the relationship. It becomes apparent that patients' needs and expectations vary widely and the treatment approach should always be individualized according to their preference for information and involvement in the decision-making process. Patient satisfaction is a complex issue that depends not only on therapeutic outcomes in terms of effi cacy and adverse events or complications but also on expectations from treatment and relationship dynamics.
Such observations augment the need for the development of care model in sexual medicine, as it happens with every other chronic condition, such as diabetes mellitus and CVD. In addition, it becomes clear that we are running to the era where personalized medicine will replace traditional schema; diagnosis is integrated with therapy for selection of the treatment as well for monitoring the outcome. Development and adaptation of a patient-centered care model in sexual medicine will increase effi cacy and safety of currently and future treatments, as well as patients' adherence, with certain benefi ts not only for our patients, but also for the healthcare systems, especially in terms of cost-effectiveness.
Future perspectives Prophylactic use of sildenafi l
Early use of vasoactive agents has been shown to rehabilitate erectile function after nerve sparing radical retropubic prostatectomy (RRP) .
In a double-blind , placebo-controlled study, sildenafi l (50 mg-100 mg) taken every night for 9 months, starting 1 month after nerve sparing radical prostatectomy was associated with recovery of spontaneous erections in 27% of patients compared with 4% of patients taking placebo . Schwartz and colleagues (2004) , in a study of 40 potent volunteers with prostate cancer who underwent RRP, showed that sildenafi l administration every other night for 6 months, substantially increases corporal smooth muscle content. The most promising prophylactic role of sildenafi l is clearly the preservation of the smooth muscle of the corpora cavernosa.
Sildenafi l in patients with lower urinary tract symptoms (LUTS)
Lower urinary tract symptoms (LUTS) are independent risk factors for sexual dysfunction in older men (Rosen et al 2003) . A possible role for PDE5i in the treatment of LUTS has been presented (McVary 2005) . Sairam and colleagues (2002) showed that ED treatment with sildenafi l improved both sexual function scores (based on IIEF) and LUTS and urinary scores correlated strongly with sexual function scores at 3 months. Mulhall and colleagues (2006) , in a group of ED patients treated with sildenafi l, similarly noticed that 60% of men improved their IPSS score, and 35% had at least a 4-point improvement in their score. If ongoing clinical research proves these preliminary data, it will open the avenue for innovative therapeutic approaches.
Sildenafi l in patients with premature ejaculation
PDE5i have been suggested to be benefi cial for patients with premature ejaculation, possibly due to a peripheral inhibition of contractile response of vas deferens, seminal vesicles, prostate, and urethra as well as a reduced central sympathetic output through a prolonged NO effect (AbdelHamid 2004) . Combination of sildenafi l with paroxetine prolongs signifi cantly intravaginal ejaculation latency time (IELT) and is associated with better intercourse satisfaction compared with paroxetine alone (Salonia et al 2002) . In a group of nonresponders to other treatments, sildenafi l combined with paroxetine and psychological -behavioral counseling alleviated premature ejaculation (Chen et al 2003) . On the contrary, sildenafi l was not superior to placebo or combination treatment with topical lidocain/prilocain cream. Further placebo-controlled, well designed studies are needed to determine whether there is any role for sildenafi l in the treatment of premature ejaculation.
Conclusions
Sildenafi l is a highly effective treatment associated with a good safety and tolerability profi le in men with ED. It is also effective in several subpopulations although effi cacy is lower in the so called diffi cult-to-treat subpopulations such as patients with diabetes mellitus or after radical prostatectomy, including men in older age groups. Sildenafi l signifi cantly improves satisfaction and quality of life for both patients and partners. Furthermore, new data from basic and clinical research suggest a possible role in the future for several other chronic conditions.
